STOCK MARKET BSE NSE

EU authorises 2 medicines for people at risk of severe COVID

The EMA described the safety profile of both medicines as “favourable," and said that despite a small number of side effects, “the medicines' benefits are greater than their risks.”

Published: 11th November 2021 11:15 PM  |   Last Updated: 11th November 2021 11:15 PM   |  A+A-

Covid medicine

Image for representation

By PTI

AMSTERDAM: The European Medicines Agency has recommended the authorisation of two new medicines against the coronavirus for people at risk of severe disease.

In a statement on Thursday, the EU drug regulator said it had concluded that the monoclonal antibody treatments — a combination of casirivimab and imdevimab, and the drug regdanvimab — have both been proven to significantly reduce the risk of hospitalisation and death in patients vulnerable to serious COVID-19.

The EMA described the safety profile of both medicines as “favourable," and said that despite a small number of side effects, “the medicines' benefits are greater than their risks.”

The drug combination of casirivimab and imdevimab is made by Roche; it was granted an emergency use license by the U.S. Food and Drug Administration last November.

The EMA said both regdanvimab and the casirivimab and imdevimab combination should be offered to people over age 12 who don't yet require oxygen support, but are at risk of worsening COVID-19.

It said the combination drug can also be used preventatively.

Both drugs must be administered intravenously.

Regdanvimab is made by Celltrion Healthcare in Hungary and has been previously authorized by South Korea.

Antibody treatments remain one of a handful of therapies that can blunt the worst effects of COVID-19, and they are the only option available to people with mild-to-moderate cases who aren't yet in the hospital.

The drugs are laboratory-made versions of virus-blocking antibodies that help fight off infections.

The treatments help the patient by supplying concentrated doses of one or two antibodies.



Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp